var data={"title":"Streptomycin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Streptomycin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6988?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=streptomycin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Streptomycin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=streptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Streptomycin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709418\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The risk of severe neurotoxic reactions is sharply increased in patients with impaired renal function or prerenal azotemia. These include disturbances of vestibular and cochlear function, optic nerve dysfunction, peripheral neuritis, arachnoiditis, and encephalopathy. The incidence of clinically detectable, irreversible vestibular damage is particularly high in patients treated with streptomycin.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Renal function should be monitored carefully; patients with renal impairment and/or nitrogen retention should receive reduced doses. The peak serum concentration in individuals with kidney damage should not exceed 20 to 25 mcg/mL.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The concurrent or sequential use of other neurotoxic and/or nephrotoxic drugs with streptomycin, including neomycin, kanamycin, gentamicin, cephaloridine, paromomycin, viomycin, polymyxin B, colistin, tobramycin, and cyclosporine should be avoided.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The neurotoxicity of streptomycin can result in respiratory paralysis from neuromuscular blockage, especially when the drug is given soon after the use of anesthesia or muscle relaxants.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The administration of streptomycin in parenteral form should be reserved for patients where adequate laboratory and audiometric testing facilities are available during therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14595275\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Streptomycin for Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223222\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Aminoglycoside;</li>\n      <li>\n        Antitubercular Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223206\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Manufacturer&rsquo;s labeling states for IM administration only, however, IV administration (off-label route) has been described (Morris 1994; Peloquin 1992; Tanoira 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Usual dosage range:</b>  IM: 15 to 30 mg/kg/day or 1 to 2 g daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Brucellosis:</b> IM: 1 g daily in 2 to 4 divided doses for 14 to 21 days (with doxycycline) (Skalsky 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Endocarditis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Enterococcal:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Manufacturer&rsquo;s labeling: IM: 1 g every 12 hours for 2 weeks, followed by 500 mg every 12 hours for 4 weeks in combination with penicillin</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternate dosing (susceptible to penicillin and streptomycin/resistant to gentamicin): Native or prosthetic valve: IM, IV: 15 mg/kg/day in divided doses every 12 hours in combination with ampicillin or penicillin; Duration of therapy: 4 weeks (native valve <b>and</b> symptoms present &lt;3 months); &ge;6 weeks (native valve <b>and</b> symptoms present &ge;3 months <b>or</b> prosthetic valve) (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Streptococcal:</i>Manufacturer&rsquo;s labeling: IM: 1 g every 12 hours for 1 week, followed by 500 mg every 12 hours for 1 week in combination with penicillin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Mycobacterium avium</i></b> <b>complex (MAC) (off-label use):</b> IM: Adjunct therapy (with macrolide, rifamycin, and ethambutol): 8 to 25 mg/kg 2 to 3 times weekly for first 2 to 3 months for severe disease (maximum single dose for age &gt;50 years: 500 mg) (Griffith 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Mycobacterium avium</i></b> <b>complex (MAC) disease, disseminated in HIV-infected patients (off-label use):</b> IM, IV: 1 g daily as optional adjunct therapy with ethambutol (plus clarithromycin or azithromycin) (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Mycobacterium kansasii </i></b> <b>disease (rifampin-resistant) (off-label use):</b> IM: 750 mg to 1 g daily  (as part of a three-drug regimen based on susceptibilities) (Campbell 2000; Griffith 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Mycobacterium ulcerans </i></b> <b>(Buruli ulcers) (off-label use):</b> IM: 15 mg/kg once daily (maximum dose: 1 g) in combination with rifampin for 8 weeks or in combination with rifampin for 4 weeks, followed by 4 weeks of rifampin and clarithromycin (WHO 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Plague:</b> IM: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Manufacturer&rsquo;s labeling:</i> 1 g twice daily for a minimum of 10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Alternate dosing:</i> 30 mg/kg/day (maximum dose: 2 g) divided every 12 hours until the patient is afebrile for at least 2 to 3 days. <b>Note:</b> Full course is considered 10 days (CDC 2014; WHO 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tuberculosis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Manufacturer&rsquo;s labeling:</i> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Daily therapy: 15 mg/kg/day (maximum: 1 g) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Directly observed therapy (DOT), twice weekly: 25 to 30 mg/kg (maximum: 1.5 g) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Directly observed therapy (DOT), 3 times weekly: 25 to 30 mg/kg (maximum: 1.5 g) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Alternate dosing:</i> IM, IV: 15 mg/kg (maximum dose: 1 g) once daily for 5 to 7 days per week for 2 to 4 months, followed by 15 mg/kg (maximum dose: 1 g) 2 to 3 times weekly (ATS 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tularemia:</b> IM: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Manufacturer&rsquo;s labeling:</i> 1 to 2 g  daily in divided doses every 12 hours for 7 to 14 days until the patients is afebrile for 5 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Alternative regimen:</i> 2 g daily in 2 divided doses for &ge;10 days (WHO 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223217\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=streptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Streptomycin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Manufacturer&rsquo;s labeling states for IM administration only, however, IV administration (off-label route) has been described (Morris 1994; Peloquin 1992; Tanoira 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Usual dosage range:</b> Infants, Children, and Adolescents: IM: 20 to 40 mg/kg/day in divided doses every 6 to 12 hours (maximum: 1,000 mg/dose; maximum daily dose: 2,000 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Indication-specific dosing:</b>  Infants, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Mycobacterium avium</i></b> <b>complex (MAC) disease, disseminated in HIV-infected patients (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Mycobacterium ulcerans </i></b> <b>(Buruli ulcers) (off-label use):</b> IM: 15 mg/kg once daily (maximum daily dose: 1,000 mg) in combination with rifampin for 8 weeks or in combination with rifampin for 4 weeks, followed by 4 weeks of rifampin and clarithromycin (WHO 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Plague (off-label use):</b> IM: 30 mg/kg/day divided every 12 hours (maximum daily dose: 2,000 mg) for 10 days or until 2 to 3 days after the temperature returns to normal (Red Book [AAP 2015]; WHO 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tularemia (off-label use):</b> IM: 15 mg/kg twice daily (maximum daily dose: 2,000 mg) for 10 days (WHO 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tuberculosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Manufacturer&rsquo;s labeling:</i> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Daily therapy: 20 to 40 mg/kg/day (maximum: 1,000 mg daily) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Directly observed therapy (DOT), twice weekly:  25 to 30 mg/kg (maximum: 1,500 mg) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Directly observed therapy (DOT), 3 times weekly: 25 to 30 mg/kg (maximum: 1,500 mg) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Alternate dosing:</i> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants, Children &le;40 kg, and Adolescents &lt;15 years or &le;40 kg: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Daily therapy: 20 to 40 mg/kg/day once daily (maximum daily dose: 1,000 mg) (ATS 2003; WHO 2009). <b>Note:</b> Some clinicians suggest every 12 hour dosing may be utilized (Berenberg 1951; Bradley 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Directly observed therapy (DOT), twice weekly: 20 mg/kg/dose twice weekly  (maximum daily dose: 1,000 mg/dose) (ATS 2003) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children and Adolescents &gt;40 kg or &ge;15 years: 15 mg/kg/day once daily (maximum daily dose: 1,000 mg) for 5 to 7 days per week for 2 to 4 months, followed by 15 mg/kg/day (maximum daily dose: 1,000 mg) 2 to 3 times weekly (ATS 2003)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223207\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> IM: Dose reductions are necessary in patients &gt;60 years.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocarditis, streptococcal: 500 mg every 12 hours for 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Alternate dosing: </i> Tuberculosis: &gt;59 years: IM, IV: 10 mg/kg (maximum: 750 mg) once daily for 5 to 7 days per week for 2 to 4 months, followed by 10 mg/kg (maximum: 750 mg) 2 to 3 times weekly (ATS 2003)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223208\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, the following adjustments have been recommended: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aronoff 2007: <b>Note:</b> Recommendations are based on doses of 1 to 2 g every 6 to 12 hours (1 g once daily for tuberculosis):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 10 to 50 mL/minute: Administer every 24 to 72 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &lt;10 mL/minute: Administer every 72 to 96 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">End-stage renal disease (ESRD):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Intermittent hemodialysis (IHD): One-half the recommended dose administered after hemodialysis on dialysis days. Note: Dosing dependent on the assumption of 3 times weekly complete IHD sessions. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Peritoneal dialysis (PD): Administration via PD fluid: 20 to 40 mg/L (20 to 40 mcg/mL) of PD fluid</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Continuous renal replacement therapy (CRRT): Administer every 24 to72 hours; monitor levels. Note: Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ATS 2003:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Tuberculosis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CrCl &lt;30 mL/minute: 12 to 15 mg/kg/dose (maximum dose: 1 g) 2 to 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): 12 to 15 mg/kg/dose (maximum dose: 1 g) 2 to 3 times weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infants, Children, and Adolescents: <b>Note:</b> Recommendations are based on doses of 20 to 40 mg/kg/dose every 24 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 7.5 mg/kg/dose every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 7.5 mg/kg/dose every 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 7.5 mg/kg/dose every 72 to 96 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">End-stage renal disease (ESRD):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Intermittent hemodialysis (IHD): 7.5 mg/kg/dose every 72 to 96 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Peritoneal dialysis (PD): Administer 7.5 mg/kg/dose every 72 to 96 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous renal replacement therapy (CRRT): Administer 7.5 mg/kg/dose every 24 hours; monitor levels. <b>Note: </b>Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22560187\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223184\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223168\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223189\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Inject deep IM into large muscle mass; midlateral thigh muscle (preferred site for children); midlateral thigh muscle or upper outer quadrant of buttocks (adults); rotate injection sites.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV (off-label route): After dilution in admixture, infuse over 30 to 60 minutes (Morris 1994; Peloquin 1992; Tanoira 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223188\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tuberculosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of tuberculosis, in combination with other appropriate antituberculosis agents, when the primary agents (eg, isoniazid, rifampin, ethambutol, pyrazinamide) are contraindicated because of toxicity or intolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nontuberculosis infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of infections caused by susceptible bacteria that are not amenable to therapy with less potentially toxic agents,including sensitive <i>Yersinia pestis</i> (plague); <i>Francisella tularensis</i> (tularemia); <i>Brucella</i>;<i> Klebsiella granulomatis</i> (donovanosis, granuloma inguinale); <i>Haemophilus ducreyi</i> (chancroid); <i>Haemophilus influenzae</i> (in respiratory, endocardial, and meningeal infections, concomitantly with another antibacterial agent); <i>Klebsiella pneumoniae</i> pneumonia (concomitantly with another antibacterial agent); <i>Escherichia coli</i>, <i>Proteus</i> spp., <i>Enterobacter aerogenes</i>, <i>K. pneumoniae</i>, and <i>Enterococcus faecalis</i> in urinary tract infections; <i>Streptococcus viridans</i>; <i>E. faecalis</i> (in endocardial infections, concomitant with penicillin); and gram-negative bacillary bacteremia (concomitant with another antibacterial agent).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470893\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Buruli ulcer (Mycobacterium ulcerans); M&eacute;ni&egrave;re&rsquo;s disease; Mycobacterium avium complex (MAC); Mycobacterium avium complex (MAC) disease, disseminated in HIV-infected patients (adolescents and adults); Mycobacterium kansasii</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223230\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Streptomycin may be confused with streptozocin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223175\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Drug fever, facial paresthesia, headache, neurotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Exfoliative dermatitis, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Azotemia, nephrotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Eosinophilia, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Amblyopia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Auditory ototoxicity, vestibular ototoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223192\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to streptomycin, other aminoglycosides, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223172\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular blockade and respiratory paralysis:<b> [US Boxed Warning]: May cause neuromuscular blockade and respiratory paralysis; especially when given soon after anesthesia or muscle relaxants.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: May cause neurotoxicity, including disturbances of vestibular and cochlear function, optic nerve dysfunction, peripheral neuritis, arachnoiditis, and encephalopathy; </b>usual risk factors include pre-existing renal impairment, concomitant neuro-/nephrotoxic medications. Ototoxicity is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage. Baseline and periodic caloric stimulation and audiometric tests are recommended with prolonged therapy. Discontinue treatment if signs of ototoxicity occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hearing impairment: Use with caution in patients with pre-existing vertigo, tinnitus, or hearing loss.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: <b> [US Boxed Warning]:  May cause nephrotoxicity.</b> Use with caution in patients with renal impairment; dose adjustment necessary in patients with renal impairment and/or nitrogen retention. Monitor renal function closely; peak serum concentrations should not surpass 20 to 25 mcg/mL in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;  Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxic and/or nephrotoxic drugs:<b> [US Boxed Warning]: Avoid concomitant or sequential use with other neurotoxic and/or nephrotoxic drugs (eg, neomycin, kanamycin, gentamicin, paromomycin, polymyxin B, colistin, tobramycin, cyclosporine).</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfite sensitivity: Some formulations may contain sodium metabisulfite; may cause allergic reactions including anaphylaxis or asthma exacerbations (some life-threatening) in susceptible patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use:<b> [US Boxed Warning]: Parenteral form should be used only where appropriate audiometric and laboratory testing facilities are available.</b> IM injections should be administered in a large muscle well within the body to avoid peripheral nerve damage and local skin reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300082\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223177\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10238&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: May enhance the nephrotoxic effect of Aminoglycosides. Arbekacin may enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ataluren: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): Streptomycin may enhance the nephrotoxic effect of Bacitracin (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephradine: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distigmine: Aminoglycosides may diminish the therapeutic effect of Distigmine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mannitol (Systemic): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.<b> Exceptions: </b>Amoxicillin; Ampicillin; Bacampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Benzathine; Penicillin V Potassium.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223180\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5722065\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Streptomycin crosses the placenta. Streptomycin may cause fetal harm if administered to a pregnant woman. There are multiple reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy. Streptomycin should never be substituted as first line therapy for the treatment of tuberculosis in pregnant women (Blumberg 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3195028\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Streptomycin is excreted into breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. As a class, aminoglycosides are expected to be poorly distributed into breast milk, limiting systemic exposure to a nursing infant. In general, modification of bowel flora may occur with any antibiotic exposure (Chung 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223182\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Baseline and periodic hearing tests (audiograms), BUN, creatinine; serum drug concentrations should be monitored in all patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223185\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Therapeutic: Peak: 20 to 30 mcg/mL; Trough: &lt;5 mcg/mL (Edson 1991); Toxic: Peak: &gt;50 mcg/mL; Trough: &gt;10 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223171\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial protein synthesis by binding directly to the 30S ribosomal subunits causing faulty peptide sequence to form in the protein chain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223191\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Poorly absorbed; IM: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes into most body tissues and fluids except the brain; small amounts enter the CSF only with inflamed meninges </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 34% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Newborns: 4 to 10 hours; Adults: ~2 to 4.7 hours; prolonged with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: IM: Within 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (29% to 89% as unchanged drug); small amount (1%) excreted in bile, saliva, sweat, and tears</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323892\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Streptomycin Sulfate Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $93.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223194\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ambistryn-S (IN);</li>\n      <li>Estrepto-Monaxin (MX);</li>\n      <li>Estreptomicina (AR);</li>\n      <li>Strepiovit (LK);</li>\n      <li>Strepto (TH);</li>\n      <li>Strepto-Hefa (DE);</li>\n      <li>Streptocin (MY);</li>\n      <li>Streptomycinum (PL);</li>\n      <li>Streptosol (ZW);</li>\n      <li>Stretopen (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ad Hoc Committee of the Scientific Assembly on Microbiology, Tuberculosis, and Pulmonary Infections, &ldquo;Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children,&rdquo; <i>Clin Infect Dis</i>, 1995, 21:9-27. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). Streptomycin. In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo; <i>Pediatrics</i> 1992, 89(1):161-5. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Thoracic Society (ATS); CDC; Infectious Diseases Society of America. Treatment of tuberculosis [published correction in <i>MMWR Recomm Rep</i>. 2005;53(51):1203]. <i>MMWR Recomm Rep</i>. 2003;52(RR-11):1-77.  <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/12836625/pubmed\" target=\"_blank\" id=\"12836625\">12836625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arguedas AG and Wehrle PP, &ldquo;New Concepts for Antimicrobial Use in Central Nervous System Infections,&rdquo; <i>Semin Pediatr Infect Dis</i>, 1991, 2(1):36-42. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486. doi: 10.1161/CIR.0000000000000296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9482564\"></a>Balyan FR, Taibah A, De Donato G, et al. Titration streptomycin therapy in Meinere's disease: long-term results. <i>Otolaryngol Head Neck Surg</i>. 1998;118(2):261-266.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/9482564/pubmed\" target=\"_blank\" id=\"9482564\">9482564</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Begg EJ and Barclay ML, &ldquo;Aminoglycosides - 50 Years On,&rdquo; <i>Br J Clin Pharmacol</i>, 1995, 39(6):597-603. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/7654476/pubmed\" target=\"_blank\" id=\"7654476\">7654476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berenberg W, Cook CD, Twinam CW. Streptomycin in pulmonary tuberculosis in children. <i>J Am Med Assoc</i>. 1951;145(14):1044-1048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/14803304/pubmed\" target=\"_blank\" id=\"14803304\">14803304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumberg HM, Burman WJ, Chaisson RE, et al, &ldquo;American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis,&rdquo; <i>Am J Respir Crit Care Med</i>, 2003, 167(4):603-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/12588714/pubmed\" target=\"_blank\" id=\"12588714\">12588714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Campbell IA, Drobinewski F, Novelli V, et al, &ldquo;Management of Opportunistic Mycobacterial Infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society,&rdquo; <i>Thorax</i>, 2000, 55(3):210-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/10679540/pubmed\" target=\"_blank\" id=\"10679540\">10679540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/12431134 /pubmed\" target=\"_blank\" id=\"12431134 \">12431134 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunha BA, &ldquo;Aminoglycosides: Current Role in Antimicrobial Therapy,&rdquo; <i>Pharmacotherapy</i>, 1988, 8(6):334-50. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/3146747/pubmed\" target=\"_blank\" id=\"3146747\">3146747</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davidson PT and Le HQ, &ldquo;Drug Treatment of Tuberculosis - 1992,&rdquo; <i>Drugs</i>, 1992, 43(5):651-73. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/1379145/pubmed\" target=\"_blank\" id=\"1379145\">1379145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Tuberculosis,&rdquo; <i>Med Lett Drugs Ther</i>, 1993, 35(908):99-101. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/8412982/pubmed\" target=\"_blank\" id=\"8412982\">8412982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edson RS and Terrell CL, &ldquo;The Aminoglycosides,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(5):519-28. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/10319086/pubmed\" target=\"_blank\" id=\"10319086\">10319086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griffith DE, Aksamit T, Brown-Elliott BA, et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases [published correction appears in <i>Am J Resp Crit Care Med</i>. 2007;175(7):744-745]. <i>Am J Resp Crit Care Med</i>. 2007;175(4):367-416.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Havlir DV and Barnes PF, &ldquo;Tuberculosis in Patients With Human Immunodeficiency Virus Infection,&rdquo; <i>N Engl J Med</i>, 1999, 340(5):367-73. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/9929528/pubmed\" target=\"_blank\" id=\"9929528\">9929528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. September 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed October 8, 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hmouda H, Laouani-Kechrid C, Karoui M, et al, &ldquo;A Rare Case of Streptomycin-Induced Toxic Epidermal Necrolysis in a Patient With Tuberculosis:  A Therapeutic Dilemma,&rdquo; <i>Ann Pharmacother</i>, 2005, 39(1):165-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/15546942/pubmed\" target=\"_blank\" id=\"15546942\">15546942</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iseman MD, &ldquo;Treatment of Multidrug-Resistant Tuberculosis,&rdquo; <i>N Engl J Med</i>, 1993, 329(11):784-91. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/8350889/pubmed\" target=\"_blank\" id=\"8350889\">8350889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim-Sing A, Kays MB, Vivien EJ, et al, &ldquo;Intravenous Streptomycin Use in a Patient Infected With High-Level Gentamicin-Resistant <i>Streptococcus faecalis</i>,&rdquo; <i>Ann Pharmacother</i>, 1993, 27(6):712-4. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/8329788/pubmed\" target=\"_blank\" id=\"8329788\">8329788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lorin MI, Hsu KH, and Jacob SC, &ldquo;Treatment of Tuberculosis in Children,&rdquo; <i>Pediatr Clin North Am</i>, 1983, 30(2):333-48. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/6602321/pubmed\" target=\"_blank\" id=\"6602321\">6602321</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morris JT, Cooper RH. Intravenous streptomycin: a useful route of administration. <i>Clin Infect Dis</i>. 1994;19(6):1150-1151.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/7888550/pubmed\" target=\"_blank\" id=\"7888550\">7888550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Passeron T, Ndir M, Aubron C, et al, &ldquo;Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Due to Streptomycin,&rdquo; <i>Acta Derm Venerol</i>, 2004, 84(1):92-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/15040497/pubmed\" target=\"_blank\" id=\"15040497\">15040497</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peloquin CA. Shortages of antimycobacterial drugs. <i>N Engl J Med</i>. 1992;326(10):714.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/1736124/pubmed\" target=\"_blank\" id=\"1736124\">1736124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Tanoira R, S&aacute;nchez-Pat&aacute;n F, Jim&eacute;nez Gir&oacute;n A, Fern&aacute;ndez Roblas R, Esteban J, Fern&aacute;ndez Guerrero ML. Tolerance and safety of intravenous streptomycin therapy in patients with tuberculosis. <i>Infection</i>. 2014;42(3):597-598.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/24748409/pubmed\" target=\"_blank\" id=\"24748409\">24748409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Prevention and Treatment of Tuberculosis Among Patients Infected With Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations. Centers for Disease Control and Prevention,&rdquo; <i>MMWR Recomm Rep</i>, 1998, 47(RR-20):1-58. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sch&uuml;tte D, Umboock A, and Pluschke G, &ldquo;Phagocytosis of <i>Mycobacterium ulcerans</i> in the Course of Rifampicin and Streptomycin Chemotherapy in Buruli Ulcer Lesions,&rdquo; <i>Br J  Derm</i>, 2009,160(2):273-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/19016694/pubmed\" target=\"_blank\" id=\"19016694\">19016694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skalsky K, Yahav D, Bishara J, et al, &ldquo;Treatment of Human Brucellosis: Systematic Review and Meta-Analysis of Randomised Controlled Trials,&rdquo; <i>BMJ</i>, 2008, 336(7646):701-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/18321957/pubmed\" target=\"_blank\" id=\"18321957\">18321957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Streptomycin [prescribing information]. Big Flats, NY: X-Gen Pharmaceuticals, Inc; December 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Scoy RE and Wilkowske CJ, &ldquo;Antituberculous Agents,&rdquo; <i>Mayo Clin Proc</i>, 1992, 67(2):179-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-drug-information/abstract-text/1347579/pubmed\" target=\"_blank\" id=\"1347579\">1347579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Operational Guidelines on Plague Surveillance, Diagnosis, Prevention and Control, 2009. Available at http://www.who.int/csr/resources/publications/plague/whocdscsredc992b.pdf. Last accessed July 9, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Guidance for Health Workers: Treatment of Mycobacterium ulcerans Disease (Buruli Ulcer), 2012. Available at http://apps.who.int/iris/bitstream/10665/77771/1/9789241503402_eng.pdf. Last accessed July 8, 2015. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &ldquo;WHO Guidelines on Tularemia,&rdquo; 2007.  Available at: http://whqlibdoc.who.int/publications/2007/9789241547376_eng.pdf. Last accessed June 29, 2012.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10238 Version 135.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709418\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14595275\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F223222\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F223206\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F223217\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F223207\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F223208\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22560187\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F223184\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F223168\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F223189\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F223188\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470893\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F223230\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F223175\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F223192\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F223172\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300082\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F223177\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F223180\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5722065\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3195028\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F223182\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F223185\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F223171\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F223191\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323892\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F223194\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10238|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=streptomycin-patient-drug-information\" class=\"drug drug_patient\">Streptomycin: Patient drug information</a></li><li><a href=\"topic.htm?path=streptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Streptomycin: Pediatric drug information</a></li></ul></div></div>","javascript":null}